PR Newswire
MARLBOROUGH, Mass., July 27, 2023
MARLBOROUGH, Mass., July 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational1 basis and 11.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $261 million or $0.18 per share (EPS), compared to $246 million or $0.17 per share a year ago, and achieved adjusted3 EPS of $0.53 for the period, compared to $0.44 a year ago.
"We had another quarter of excellent results fueled by our innovative portfolio, strong commercial execution and the high performance of our global team," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We are excited about our long-term outlook and robust pipeline of unique innovations to address unmet patient needs."
Second quarter financial results and recent developments:
1. Operational net sales growth excludes the impact of foreign currency fluctuations. |
2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. |
3. Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items. |
4.Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation. |
Net sales for the second quarter by business and region:
| | | | | Increase/(Decrease) | ||||||||
| | Three Months Ended June 30, | | Reported | | Impact of | | Operational Basis | | Impact of | | Organic | |
(in millions) | 2023 | 2022 | | | | | | ||||||
| Endoscopy | $ 631 | $ 560 | | 12.7 % | | 0.8 % | | 13.6 % | | (1.9) % | | 11.6 % |
| Urology | 485 | 450 | | 7.8 % | | 0.6 % | | 8.4 % | | — % | | 8.4 % |
| Neuromodulation | 244 | 239 | | 2.5 % | | 0.3 % | | 2.8 % | | — % | | 2.8 % |
| MedSurg | 1,360 | 1,248 | | 9.0 % | | 0.6 % | | 9.6 % | | (0.9) % | | 8.8 % |
| Cardiology | 1,704 | 1,517 | | 12.3 % | | 1.1 % | | 13.4 % | | — % | | 13.4 % |
| Peripheral Interventions | 535 | 478 | | 11.9 % | | 1.6 % | | 13.5 % | | — % | | 13.5 % |
| Cardiovascular | 2,239 | 1,996 | | 12.2 % | | 1.2 % | | 13.4 % | | — % | | 13.4 % |
Net Sales | $ 3,599 | $ 3,244 | | 11.0 % | | 1.0 % | | 12.0 % | | (0.3) % | | 11.6 % | |
| | | | | | | | | | | | | |
| | | | | Increase/(Decrease) | | | | | ||||
| | Three Months Ended | | Reported | | Impact of | | Operational Basis | | | | | |
(in millions) | 2023 | 2022 | | | | ||||||||
| U.S. | $ 2,110 | $ 1,933 | | 9.1 % Werbung Mehr Nachrichten zur Boston Scientific Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. |